Why the study?
Variants in the NKX2.5 gene are commonly linked to CHD, but their associations with conduction disease, dangerous ventricular arrhythmias, and sudden cardiac death have received relatively less attention in the literature.
A novel NKX2.5 gene variant (c.437C > A; p. Ser146) is associated with a spectrum of familial heart disease, highlighting the need to screen for potentially dangerous ventricular arrhythmias in these patients.
Answers are grounded in this paper and cite their sources.
NKX2.5 variants may warrant arrhythmia surveillance in CHD families; leaves open prospective validation of sudden-death risk.
INTRODUCTION: The NKX2.5 gene is an important cardiac developmental transcription factor, and variants in this gene are most commonly associated with CHD. However, there is an increased need to recognise associations with conduction disease and potentially dangerous ventricular arrhythmias. There is an increased risk of arrhythmia and sudden cardiac death in patients with NKX2.5 variants, an association with relatively less attention in the literature. METHODS: We created a family pedigree and reconstructed familial relationships involving numerous relatives with CHD, conduction disease, and ventricular non-compaction following the sudden death of one family member. Two informative but distantly related family members had genetic testing to determine the cause of arrhythmias via arrhythmia/cardiomyopathy gene testing, and we identified obligate genetic-positive relatives based on family relationships and Mendelian inheritance pattern. RESULTS: We identified a novel pathogenic variant in the NKX2.5 gene (c.437C > A; p. Ser146*), and segregation analysis allowed us to link family cardiac phenotypes including CHD, conduction disease, left ventricular non-compaction, and ventricular arrhythmias/sudden cardiac death. CONCLUSIONS: We report a novel NKX2.5 gene variant linking a spectrum of familial heart disease, and we also encourage recognition of the association between NKX2.5 gene and potentially dangerous ventricular arrhythmias, which will inform clinical risk stratification, screening, and management.
No takes yet. Share an insight, caveat, or question.
Helm et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: